EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Biweekly GLP ‐ 1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

Wei Ding iD, Qing Liu iD, Qiong Luo iD, Xiaojun Yao iD, Xingxing Fan iD

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11143-11177

DOI: 10.1111/dom.71304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.09.2026. Verfasst von Wei Ding und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine & Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology…. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Obesity. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nanjing Major Science and Technology Special Project (Life and Health), Nanjing Chi Heal Biomedicine Technology Co., Ltd., Shenzhen China Resources Gosun Pharmaceuticals Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability.

Methods

CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays. Pharmacokinetics were profiled in SD rats; metabolic efficacy was evaluated in B6/ob and DIO mice (CT130 biweekly vs semaglutide weekly). Receptor trafficking dynamics and cholesterol regulation were dissected mechanistically. Toxicology was assessed in rodents and a primate pilot study.

Results

CT130 retained high GLP‑1R affinity (EC 50 = 21 pM) and exhibited a prolonged half‑life (13.9 h, 1.4‑fold vs semaglutide). Biweekly CT130 outperformed weekly semaglutide in body weight reduction, glucose tolerance, TC, LDL‑C, body fat percentage and other metabolic indicators. Drug‑free intervals enabled near‑complete GLP‑1R recycling, termed “GLP‑1R recovery”, preserving receptor homeostasis, whereas semaglutide drove progressive internalization. CT130 also alleviated constipation risk (increased fecal water) and uniquely lowered cholesterol by suppressing SREBP‑2, which upregulated LDLR while decoupling from PCSK9 induction, thereby promoting fecal cholesterol excretion without altering bile acid flux. No pathological changes were observed even at tens to 200 times the semaglutide dose. In monkeys, two biweekly doses induced > 10% weight loss with good safety.

Conclusions

CT130 is a safe, once biweekly preclinical candidate that incorporates drug free intervals to allow GLP 1R restore. It delivers robust, lasting metabolic benefits with improved gastrointestinal tolerability, and offering a template for next generation long acting GLP 1R agonists.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsObesityGastrointestinal TractAnimalsSemaglutideRatsMaleGlucagon-Like Peptide-1 ReceptorHomeostasisRats, Sprague-DawleyMiceHumansMacaca fascicularisMice, Inbred C57BLDrug Administration ScheduleWeight Loss

Stichwörter der Autor:innen

GLP‐1 receptor agonistGLP‐1R homeostasisPCSK9SREBP‐2cholesterol metabolismdrug‐free intervalenterohepatic axisgastrointestinal tolerabilityobesitysemaglutide

Substanzen

SemaglutideGlucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorHypoglycemic AgentsGlp1r protein, rat

Autor:innen und Institutionen

  • School of Pharmacy, Faculty of Medicine & Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Macau, China.
  • Nanjing Chi Heal Biomedicine Technology Co., Ltd, Nanjing, China.
  • School of Biomedical Engineering, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Suzhou Institute for Advanced Research, University of Science and Technology of China, Suzhou, China.
  • Department of Basic Medical Sciences, Changsha Medical University, Changsha, Hunan, China.
  • Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha, Hunan, China.

ORCID-Profile: Wei Ding, Qing Liu, Qiong Luo, Xiaojun Yao, Xingxing Fan

Förderung

  • Nanjing Major Science and Technology Special Project (Life and Health)
  • Nanjing Chi Heal Biomedicine Technology Co., Ltd.
  • Shenzhen China Resources Gosun Pharmaceuticals Co., Ltd.

Zitieren

APA

Ding, W., Liu, Q., Luo, Q., Yao, X., & Fan, X. (2026). A Biweekly GLP ‐ 1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability. Diabetes, Obesity and Metabolism, 28(12), 11143-11177. https://doi.org/10.1111/dom.71304

Vancouver

Ding W, Liu Q, Luo Q, Yao X, Fan X. A Biweekly GLP ‐ 1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability. Diabetes, Obesity and Metabolism. 2026;28(12):11143-11177. doi:10.1111/dom.71304

BibTeX
@article{Ding2026,
  author = {Ding, Wei and Liu, Qing and Luo, Qiong and Yao, Xiaojun and Fan, Xingxing},
  title = {A Biweekly GLP ‐ 1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11143--11177},
  doi = {10.1111/dom.71304}
}
Kostenlos starten →